Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

(2016) Bo Jia et al.   Hematology

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

(2016) De-Ning Ma et al.   Journal of Hematology & Oncology

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis

(2013) Lin Gui et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Distribution of Lymphoid Neoplasms in China

(2012) Jian Sun et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution

(2011) Qun-Pei Yang et al.   Diagnostic Pathology

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY